Get the Stockscreener App
9.10
4.61%
-0.44
Pre-market:
9.12
0.02
+0.22%
Neogenomics Inc stock is traded at $9.10, with a volume of 1.41M.
It is down -4.61% in the last 24 hours and down -23.98% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$9.54
Open:
$9.64
24h Volume:
1.41M
Relative Volume:
0.77
Market Cap:
$1.18B
Revenue:
$727.33M
Net Income/Loss:
$-108.03M
P/E Ratio:
-10.78
EPS:
-0.844
Net Cash Flow:
$-21.78M
1W Performance:
-7.33%
1M Performance:
-23.98%
6M Performance:
+12.90%
1Y Performance:
-2.57%
1-Day Range:
$9.08
$9.70
1-Week Range:
$9.035
$10.23
52-Week Range:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.10 | 1.24B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics (NEO) accounting chief granted new options and RSUs - Stock Titan
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan
NeoGenomics (NEO) COO receives new stock option and RSU grants - Stock Titan
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan
NeoGenomics at TD Cowen Conference: Strategic Growth Insights - Investing.com South Africa
NeoGenomics Stock Price Drops Below 200-Day Average - National Today
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan
Oversold Conditions For NeoGenomics (NEO) - Nasdaq
NEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NEO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Earnings are out: How did SWFL companies perform? - Naples Daily News
Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test - Bloomberg Law News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Yahoo Finance
(NEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tu - PharmiWeb.com
NeoGenomics Launches RaDaR ST Molecular Residual Disease Test - marketscreener.com
NeoGenomics, Inc. Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - marketscreener.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - The Joplin Globe
Is NeoGenomics’ (NEO) RaDaR ST Medicare Win Quietly Redefining Its Oncology Diagnostics Edge? - Sahm
NeoGenomics, Inc. Trade Ideas — FWB:NG9 - TradingView
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction - MSN
NeoGenomics (NEO) COO logs RSU vesting and tax share withholding - Stock Titan
Equity moves for NeoGenomics (NASDAQ: NEO) CFO Jeffrey Sherman - Stock Titan
NeoGenomics (NEO) EVP nets new shares from RSU vesting and tax withholding - Stock Titan
NeoGenomics (NEO) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
NeoGenomics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call - Finviz
NeoGenomics, Inc. (NEO) Stock Analysis: A 47% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call - Yahoo Finance
Market Catalysts: What are Calix Incs technical support levelsMarket Trend Report & Verified Momentum Watchlists - baoquankhu1.vn
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - Yahoo Finance
NeoGenomics, Inc. $NEO Shares Bought by White Pine Capital LLC - MarketBeat
NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc - MarketBeat
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Finviz
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Why is NeoGenomics Inc. stock going upM&A Rumor & Free High Accuracy Swing Entry Alerts - mfd.ru
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock - Defense World
NeoGenomics Q4 Earnings Call Highlights - Defense World
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
NeoGenomics (NASDAQ:NEO) Trading Down 8.9%Should You Sell? - MarketBeat
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses ExpectationsNews and Statistics - IndexBox
Weekly Trades: Will ChoiceOne Financial Services Inc benefit from green energy policies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Why NeoGenomics (NEO) Shares Are Falling Today - Finviz
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook - Finviz
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):